Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
Researchers identify new genetic disorder that affects brain, craniofacial skeleton
20 January 2021Hematopoietic stem cell transplants may provide long-term benefit for people with multiple sclerosis
20 January 2021Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
Renal cell carcinoma (RCC) is the most common form of kidney cancer. In 2018, there were an estimated 403,000 new cases of RCC and 175,000 deaths due to kidney cancer worldwide. Currently, the 5-year survival rate for patients with metastatic RCC is only about 12 percent. Current treatments include inhibitors of the VEGF and PD-1 pathways. However, resistance to therapy occurs in most patients and new combination treatments are still needed to enhance the efficacy of these current approaches.
